Dukiprubart

N/A

Report date: 2026/05/20 20:02:01
First In Class

Base Information

Drug NameDukiprubart
Drug Alias NameSGC-001ZYB-0069
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionS100 Calcium Binding Protein A8 antagonistsS100 calcium binding protein A9 inhibitors
TargetsS100 Calcium Binding Protein A8S100 calcium binding protein A9
Therapy Area/IndicationsST Elevation Myocardial InfarctionAnterior Wall Myocardial InfarctionMyocardial Infarction
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Sungen Biomedical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Sungen Biomedical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsST Elevation Myocardial InfarctionAnterior Wall Myocardial InfarctionMyocardial Infarction
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A